Indication for neutralizing monoclonal antibodies for treatment of COVID-19 in real life: the big gap with controlled randomized trials

Q4 Medicine

Revue Medicale de Bruxelles Pub Date : 2022-01-01 DOI:10.30637/2022.22-043

M. Hildebrand, J. Goffard

引用次数: 0

Abstract

Anti-SARS-CoV-2 neutralizing monoclonal antibodies treatments have been studied through randomized controlled trials and have demonstrated efficacy for prevention and early COVID-19 treatment. Their use in real life is different from studies in many points. Variant changes, vaccination coverage, treated groups with nAbs which are different from clinical trials are topics discussed in this paper.

查看原文本刊更多论文

中和单克隆抗体在现实生活中治疗COVID-19的适应症:与对照随机试验的巨大差距

通过随机对照试验研究了抗sars - cov -2中和单克隆抗体治疗方法，并证明了预防和早期治疗COVID-19的有效性。它们在现实生活中的应用在许多方面与研究不同。变异变化、疫苗接种覆盖率、与临床试验不同的nab治疗组是本文讨论的主题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revue Medicale de Bruxelles Medicine-Medicine (all)

CiteScore

0.10

自引率

0.00%

发文量

期刊介绍： Des articles originaux et de synthèse, des cas cliniques et anatomopathologiques, des actualités thérapeutiques, des comptes rendus de symposia, des imageries, une rubrique consacrée à l"histoire de la médecine, des annonces de prix, ainsi que le programme de réunions scientifiques et sociales, des nominations récentes, des propositions d"emploi, etc.